AT-406

Cat. # SI9890

Background: An oral, Smac mimetic that also serves as an inhibitor of apoptosis proteins: XIAP, cIAP1, and cIAP2. AT-406 has been shown to inhibit survival of cancer cells and is currently in phase 1 clinical trials for human cancer treatment[1].

Application: Inhibition of XIAP, cIAP1 and cIAP2

Product Information:

CAS No.	1071992-99-8
Purity:	>99%
Molecular Weight:	561.71 Da
Physical State:	Powder
Quantity:	5mg
Solubility:	DMSO (112mg/ml); Ethanol (<112mg/ml); Water (<1mg/ml)
Storage:	Store desiccated as supplied at -20ºC for 2 years.



Formula:

$C_{32}H_{43}N_5O_4$

References

1. Cai Q, et al. (2011). “A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.” J Med Chem 54(8): 2714-2726.